U. Ilgen Et Al. , "Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis," CLINICAL RHEUMATOLOGY , vol.36, no.2, pp.367-372, 2017
Ilgen, U. Et Al. 2017. Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis. CLINICAL RHEUMATOLOGY , vol.36, no.2 , 367-372.
Ilgen, U., Yayla, M. E., & Duzgun, N., (2017). Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis. CLINICAL RHEUMATOLOGY , vol.36, no.2, 367-372.
Ilgen, Ufuk, MÜÇTEBA ENES YAYLA, And Nursen Duzgun. "Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis," CLINICAL RHEUMATOLOGY , vol.36, no.2, 367-372, 2017
Ilgen, Ufuk Et Al. "Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis." CLINICAL RHEUMATOLOGY , vol.36, no.2, pp.367-372, 2017
Ilgen, U. Yayla, M. E. And Duzgun, N. (2017) . "Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis." CLINICAL RHEUMATOLOGY , vol.36, no.2, pp.367-372.
@article{article, author={Ufuk Ilgen Et Al. }, title={Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis}, journal={CLINICAL RHEUMATOLOGY}, year=2017, pages={367-372} }